DeepCure
DeepCure is a Boston-based, pre-revenue biotech that uses an integrated AI, physics-based, and automated chemistry platform (PocketExpander, MolGen, DiscoveryHub, Inspired Chemistry) to discover oral small molecule drugs for immune and inflammatory diseases, pursuing a licensing and co-development model with pharmaceutical partners.
- Company typePrivate
- Founded2020
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What DeepCure does
DeepCure is a privately held, Boston-headquartered biotechnology company developing AI-driven small molecule therapeutics for immune and inflammatory diseases. Its integrated platform, branded Inspired Chemistry, combines three proprietary components: PocketExpander, which uses AI plus quantum-mechanical and molecular dynamics simulations to map protein surfaces and identify druggable features on targets without known ligands; MolGen, a deep reinforcement learning system that generates readily synthesizable compounds across millions of building blocks and more than 200 chemical reactions; and DiscoveryHub, a collaborative DMTA workflow layer. The platform is closed-loop with an automated robotic wet lab (the Inspired Chemistry synthesis module, built in partnership with Biosero) that has demonstrated parallel synthesis of nirmatrelvir plus 56 analogs.
The company's pipeline comprises three oral small molecule programs: DC-9476, a third-generation selective BRD4-BD2 inhibitor in IND-enabling studies for rheumatoid arthritis, Still's disease, and hidradenitis suppurativa; DC-15442, an oral STAT6 inhibitor named as a development candidate in June 2025 for asthma and atopic dermatitis with preclinical efficacy comparable to dupilumab; and an early-discovery TNFα program for autoimmune indications. DeepCure has also extended its AI stack into knowledge retrieval through a chemistry LLM workflow developed with Google Cloud Platform and CloudWerx, and is generating clinical evidence via a collaboration with the Leeds Institute of Rheumatic and Musculoskeletal Medicine.
DeepCure is pre-revenue and pursues a licensing and co-development business model targeting pharmaceutical and biotech partners. The company has raised approximately $70.4 million across seed, Series A, and Series A-1 rounds from investors including Morningside Ventures, TLV Partners, Sapir Venture Partners, Benon Group, and IAG Capital Partners, with Series A proceeds earmarked for establishing operations in Greece and Israel. Its go-to-market is enterprise business development led by CBO Han Lim (formerly CBO of Atomwise), supported by scientific thought leadership at industry conferences and preclinical data publications.
DeepCure firmographics
Firmographics- Name
- DeepCure
- Legal name
- Deepcure
- Website
- https://deepcure.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DeepCure is a Boston-based, pre-revenue biotech that uses an integrated AI, physics-based, and automated chemistry platform (PocketExpander, MolGen, DiscoveryHub, Inspired Chemistry) to discover oral small molecule drugs for immune and inflammatory diseases, pursuing a licensing and co-development model with pharmaceutical partners.
- Ownership category
- akta.pro rank
DeepCure industry classification
Industry- Product category
- Biotechnology / AI-driven small molecule drug discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where DeepCure is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
DeepCure business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations
Revenue model
- Therapeutic Development & Licensing: DeepCure is a pre-revenue biotech company developing a pipeline of novel small molecule drugs for immune and inflammatory diseases. Its primary anticipated revenue streams are out-licensing deals, co-development partnerships with pharmaceutical companies, and ultimately product approvals. The company is advancing DC-9476 (BRD4-BD2 inhibitor, IND-enabling for RA, Still's disease, hidradenitis suppurativa) and DC-15442 (STAT6 inhibitor, development candidate for asthma, atopic dermatitis), with a TNFα program in early discovery.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
DeepCure product offering
Product offeringCore offering
DeepCure uses AI and physics-based computational methods to discover and develop novel oral small molecule therapeutics for immune and inflammatory diseases, integrating molecular generation, protein surface mapping, and automated robotic synthesis into a single drug discovery platform. Its current product offering consists of a pipeline of preclinical and IND-enabling drug candidates (DC-9476 for autoimmune diseases, DC-15442 for asthma/atopic dermatitis, and a TNFα program) that it out-licenses or co-develops with pharmaceutical partners. The company does not sell commercial products directly and is pre-revenue, relying on licensing deals, co-development partnerships, and potential acquisitions.
Product overview
DeepCure is an immunology therapeutics company developing novel small molecule drugs for immune and inflammatory diseases using an integrated AI-powered drug discovery platform called Inspired Chemistry. The platform comprises three core proprietary technologies: PocketExpander (AI and physics-based protein surface mapping), MolGen (reinforcement learning-driven molecular generation), and DiscoveryHub (collaborative research workflow management). The company is advancing a pipeline of oral small molecule therapeutics including DC-9476 (BRD4-BD2 inhibitor for rheumatoid arthritis, IND-enabling stage) and DC-15442 (STAT6 inhibitor for asthma/atopic dermatitis, development candidate stage), with a TNFα program in early discovery. DeepCure operates from Boston with R&D sites in Israel and Greece.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- DC-15442 demonstrated nearly 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab in preclinical models
- +2 more outcomes
Companies that use DeepCure
Customer profileSegments2 records
Ideal customer profiles1 record
DeepCure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
DeepCure partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Google Cloud Platform (GCP)coreDeepCure completed a pilot program with Google Cloud Platform and CloudWerx (CWX) to build an AI-driven workflow that extracts chemical insights from unstructured literature to answer complex queries on organic chemistry, demonstrating the potential for chemistry LLMs to increase productivity in medicinal chemistry.
- CloudWerx (CWX)coreCloudWerx collaborated with DeepCure and Google Cloud Platform to build an AI-driven workflow for extracting chemical insights from unstructured literature, demonstrating chemistry LLM capabilities for medicinal chemistry productivity.
- Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM)coreDeepCure announced a collaboration with the Leeds Institute of Rheumatic and Musculoskeletal Medicine to investigate DC-9476, a third-generation selective BRD4 (BD2) inhibitor, as a potential treatment for rheumatoid arthritis patients who do not respond well to current standard of care. The partners will conduct a study using blood samples and joint biopsies from various patient subgroups, focusing on those resistant to current treatments.
- BioserocoreDeepCure and Biosero collaborated to establish a fully automated, AI-powered chemistry synthesis platform. This collaboration enabled DeepCure to accelerate synthesis of AI-designed molecules and validate its Inspired Chemistry™ platform.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
DeepCure competitors and assessment
Company assessmentDirect peers
- Atomwise: AI small molecule discovery platform using structure-based deep learning for hit identification and lead optimization. DeepCure's CBO previously served as Atomwise's CBO, making it a closely comparable business model and direct competitor for pharma BD.
- Exscientia: AI-driven precision medicine company using a Centaur Chemist™ platform for small molecule design. Comparable as an AI-first small molecule discovery peer pursuing pharma partnerships and an internal pipeline.
- Schrödinger: Physics-based computational chemistry platform for molecular design, combined with an internal therapeutics pipeline. Highly comparable to DeepCure's use of quantum mechanical and molecular dynamics methods in PocketExpander.
- Insilico Medicine: End-to-end AI-driven drug discovery company combining generative chemistry, target ID, and automated biology. Most directly comparable to DeepCure as a fellow AI-native small molecule discovery platform pursuing IND-ready candidates.
- BenevolentAI: AI drug discovery company combining knowledge graphs and ML for target ID and small molecule discovery. Comparable as a platform-first discovery company with therapeutic programs in immunology/inflammation-adjacent areas.
- XtalPi: AI + physics-based drug discovery company combining quantum physics, cloud computing, and robotic synthesis. Comparable end-to-end platform architecture and emphasis on automation in compound generation.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput wet-lab experimentation with machine learning. Comparable as a technology-first discovery company advancing internal pipeline candidates through preclinical and clinical stages.
Broad incumbents
- Generate:Biomedicines: Flagship Pioneering–backed generative AI biology company designing novel therapeutics. Operates at broader scale and across modalities, but competes for the same pharma BD mindshare and validates the AI-discovery category.
Emerging players
- Cradle Bio: AI protein design and engineering company with generative models for biologics. Less directly overlapping (biologics vs. DeepCure's small molecules), but a comparable AI-native discovery company targeting pharma BD.
- Isomorphic Labs: Alphabet-founded AI drug design company applying DeepMind protein-modeling breakthroughs to small molecule design. Emerging competitor with comparable AI-physics approach but deeper capital and pharma partnerships.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key highlights7 records
Customer concentration
DeepCure social profiles
Digital presenceDeepCure financial estimates
Financial estimateRevenue estimate
Valuation estimate
DeepCure leadership team
Management profileNumber of profiles
Profiles7 records
DeepCure funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DeepCure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DeepCure
What does DeepCure do?
DeepCure uses AI and physics-based computational methods to discover and develop novel oral small molecule therapeutics for immune and inflammatory diseases, integrating molecular generation, protein surface mapping, and automated robotic synthesis into a single drug discovery platform. Its current product offering consists of a pipeline of preclinical and IND-enabling drug candidates (DC-9476 for autoimmune diseases, DC-15442 for asthma/atopic dermatitis, and a TNFα program) that it out-licenses or co-develops with pharmaceutical partners. The company does not sell commercial products directly and is pre-revenue, relying on licensing deals, co-development partnerships, and potential acquisitions.
Is DeepCure a public or private company?
DeepCure is a private company. It is classified as venture growth investor backed and is currently operating.
When was DeepCure founded?
DeepCure was founded in 2020. It employs 11 to 50 people.
Where is DeepCure based?
DeepCure is headquartered in Boston, United States, in the North America region.
How does DeepCure make money?
One revenue line is on record: therapeutic Development & Licensing.
Who are DeepCure's main competitors?
Direct peers on record are Atomwise, Exscientia, Schrödinger, Insilico Medicine, BenevolentAI, XtalPi and Recursion Pharmaceuticals. Generate:Biomedicines is listed as a broad incumbent. Emerging players are Cradle Bio and Isomorphic Labs.
Does DeepCure have an API?
No public API is recorded for DeepCure.
What industry is DeepCure in?
DeepCure's product category is Biotechnology / AI-driven small molecule drug discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.